Selective inhibition of the platelet phosphoinositide 3-kinase p110β as promising new strategy for platelet protection during extracorporeal circulation

Thrombosis and Haemostasis

Volumn 99, Issue 3, 2008, Pages 609-615

  Straub, Andreas ^a,b   Wendel, Hans Peter ^a   Dietz, Klaus ^a   Schiebold, Daniela ^a   Peter, Karlheinz ^b   Schoenwaelder, Simone M ^c   Ziemer, Gerhard ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

GP IIb IIIa; Platelet pharmacology; Surgery

Indexed keywords

9 (1 ANILINOETHYL) 7 METHYL 2 MORPHOLINOPYRIDO[1,2 A]PYRIMIDIN 4 ONE; BETA THROMBOGLOBULIN; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHOINOSITIDE 3 KINASE P110 BETA; PHOSPHOINOSITIDE 3 KINASE P110 BETA INHIBITOR; TGX 297; TIROFIBAN; UNCLASSIFIED DRUG;

ANALYSIS OF VARIANCE; ANTIGEN EXPRESSION; ARTICLE; BLEEDING; CELL INTERACTION; CELL PROTECTION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACORPOREAL CIRCULATION; FLOW CYTOMETRY; GRANULOCYTE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; PRIORITY JOURNAL; SHEAR STRESS; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTITHROMBIN III; BETA-THROMBOGLOBULIN; BLOOD PLATELETS; EXTRACORPOREAL CIRCULATION; FIBRINOGEN; GRANULOCYTES; HEMOGLOBINS; HUMANS; MALE; MICROSCOPY, ELECTRON, SCANNING; MORPHOLINES; PEPTIDE HYDROLASES; PLATELET ACTIVATION; PLATELET ADHESIVENESS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PLATELET MEMBRANE GLYCOPROTEIN IIB; PROTEIN KINASE INHIBITORS; PYRIMIDINONES; RESEARCH DESIGN; STRESS, MECHANICAL; TIME FACTORS; TYROSINE;

EID: 42249111545     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH07-07-0452     Document Type: Article

References (27)

1. Kouchoukos NT, Karp RB, Blackstone EH, et al. Kirklin/Barratt-Boyes Cardiac surgery. 3rd edition. USA Elsevier Science: 2003.
2. Paparella D, Brister SJ and Buchanan MR. Coagulation disorders of cardiopulmonary bypass: a review. Intensive Care Med 2004; 30: 1873-1881.
3. Weerasinghe A, Taylor KM. The platelet in cardiopulmonary bypass. Ann Thorac Surg 1998; 66: 2145-2152.
4. Chang AC, McKenzie ED. Mechanical cardiopulmonary support in children and young adults: extracorporeal membrane oxygenation, ventricular assist devices, and long-term support devices. Pediatr Cardiol 2005; 26: 2-28.
5. King BO, Whittow ES, Serna DL, et al. Tirofiban administration attenuates platelet and platelet-neutrophil conjugation but not neutrophil degranulation during in vitro VAD circulation. Asaio J 2001; 47: 282-287.
6. Straub A, Wendel HP, Azevedo R, et al. The GP IIb/IIIa inhibitor abciximab (ReoPro) decreases activation and interaction of platelets and leukocytes during in vitro cardiopulmonary bypass simulation. Eur J Cardiothorac Surg 2005; 27: 617-621.
7. Straub A, Azevedo R, Beierlein W, et al. Tirofiban (Aggrastat) protects platelets and decreases platelet-granulocyte binding in an extracorporeal circulation model. Thorac Cardiovasc Surg 2006; 54: 162-167.
8. Hiramatsu Y, Gikakis N, Anderson HL, 3rd, et al. Tirofiban provides "platelet anesthesia" during cardiopulmonary bypass in baboons. J Thorac Cardiovasc Surg 1997; 113: 182-193.
9. Harder S, Klinkhardt U, Alvarez JM. Avoidance of bleeding during surgery in patients receiving anticoagulant and/or antiplatelet therapy: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet 2004; 43: 963-981.
10. Jackson SP, Schoenwaelder SM, Goncalves I, et al. PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat Med 2005; 11: 507-514.
11. Schoenwaelder SM, Ono A, Sturgeon S, et al. Identification of a unique co-operative phosphoinositide 3-kinase signaling mechanism regulating integrin alpha IIb beta 3 adhesive function in platelets. J Biol Chem 2007; 282: 28648-28658.
12. Schneider DJ, Herrmann HC, Lakkis N, et al. Increased concentrations of tirofiban in blood and their correlation with inhibition of platelet aggregation after greater bolus doses of tirofiban. Am J Cardiol 2003; 91: 334-336.
13. Weber N, Wendel HP, Ziemer G. Hemocompatibility of heparin-coated surfaces and the role of selective plasma protein adsorption. Biomaterials 2002; 23: 429-439.
14. Straub A, Azevedo R, Beierlein W, et al. Glycoprotein IIb/IIIa inhibition reduces prothrombotic events under conditions of deep hypothermic circulatory arrest. Thromb Haemost 2005; 94: 115-122.
15. Doenicke A, Roizen MF, Hoernecke R, et al. Haemolysis after etomidate: comparison of propylene glycol and lipid formulations. Br J Anaesth 1997; 79: 386-388.
16. Addonizio VP, Colman RW. Platelets and extracorporeal circulation. Biomaterials 1982; 3: 9-15.
17. Goto S, Salomon DR, Ikeda Y, et al. Characterization of the unique mechanism mediating the shear-dependent binding of soluble von Willebrand factor to platelets. J Biol Chem 1995; 270: 23352-23361.
18. Naimushin YA, Mazurov AV. Von Willebrand factor can support platelet aggregation via interaction with activated GPIIb-IIIa and GPIb. Platelets 2004; 15: 419-425.
19. Pontiggia L, Steiner B, Ulrichts H, et al. Platelet microparticle formation and thrombin generation under high shear are effectively suppressed by a monoclonal antibody against GPIba. Thromb Haemost 2006; 96: 774-780.
20. Bizzarri F, Scolletta S, Tucci E, et al. Perioperative use of tirofiban hydrochloride (Aggrastat) does not increase surgical bleeding after emergency or urgent coronary artery bypass grafting. J Thorac Cardiovasc Surg 2001; 122: 1181-1185.
21. Dyke CM, Bhatia D, Lorenz TJ, et al. Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from PURSUIT. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrelin Therapy. Ann Thorac Surg 2000; 70: 866-872.
22. Genoni M, Zeller D, Bertel O, et al. Tirofiban therapy does not increase the risk of hemorrhage after emergency coronary surgery. J Thorac Cardiovasc Surg 2001; 122: 630-632.
23. Yeo EL, Sheppard JA, Feuerstein IA. Role of P-selectin and leukocyte activation in polymorphonuclear cell adhesion to surface adherent activated platelets under physiologic shear conditions (an injury vessel wall model). Blood 1994; 83: 2498-2507.
24. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest 2005; 115: 3378-3384.
25. Rinder CS, Bonan JL, Rinder HM, et al. Cardiopulmonary bypass induces leukocyte-platelet adhesion. Blood 1992; 79: 1201-1205.
26. Wilhelm CR, Ristich J, Kormos RL, et al. Monocyte tissue factor expression and ongoing complement generation in ventricular assist device patients. Ann Thorac Surg 1998; 65: 1071-1076.
27. Redlich H, Vickers J, Lösche W, et al. Formation of platelet-leukocyte conjugates in whole blood. Platelets 1997; 8: 419-426.